Podcasts about Dart

(0:00) Giants introduce HC John Harbaugh(14:00) Harbaugh on why he chose Giants(15:00) Harbaugh's dynamic with Joe Schoen(40:00) Harbaugh praises Jaxson Dart - will Harbaugh get Dart to avoid taking bit hits?(46:00) Expectations for Giants in 2026  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How many QBs would you take ahead of Jaxson Dart as of now? And where will the Jets get their next QB from? And Stump Rothenberg! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Shaun unveils his full Cinco de Lunch countdown, ranking the five most exciting Giants days since Super Bowl XLVI and explaining why today stands above them all. The list revisits moments Giants fans almost forget, like clinching a playoff spot on New Year's Day 2023 and the unexpected thrill of beating the Vikings in the 2022 playoffs, even knowing how quickly things unraveled afterward. The conversation then jumps to recent hope. Draft night optimism with Abdul Carter and Jaxson Dart, followed by Dart's prime time statement game against the Eagles, is framed as a turning point fans will look back on as the night he truly arrived. At the top of the list is today. John Harbaugh becoming the head coach of the New York Giants is declared the most exciting Giants day since 2012, regardless of what he says at the podium. The segment also addresses fair concerns about Harbaugh's late game decisions in Baltimore, with comparisons to Andy Reid and why elite coaches can evolve after a long run in one place. As dignitaries arrive and the building buzz grows, Shaun makes it clear why this moment feels different. For Giants fans, the shelf life starts now, and the optimism is real.

New Giants head coach John Harbaugh sits down with Evan and Tiki right after his introduction and gets into what made this job feel inevitable, why the Giants are an iconic fit, and what he believes the team can become. Harbaugh talks about leaving Baltimore, his relationship with ownership, and the role his family and faith play in how he approaches the grind of coaching. On the football side, he dives into what he saw on tape, why the run game starts up front, and what excites him about the Giants' backfield and offensive line. He discusses Abdul Carter's rookie finish, the importance of physicality, and how he wants the Giants to win in the margins. Harbaugh also explains how he views Jaxson Dart as a modern quarterback who gives an offense options, from RPOs to quarterback driven concepts that stress defenses. Harbaugh updates where he is in the coordinator search, confirms he is meeting with the current staff, and even entertains the idea of reaching out to familiar names from his past. He also shares what he wants Giants fans to feel watching this team, pride, identity, and effort that shows up on tape every week. The interview closes with a few lighter moments, including the early morning workout routine and the competitive edge that comes with a fresh start in New York.

Heath Cummings is BACK from vacation and answering YOUR questions. (0:00) Intro (2:05) Rookie Draft Questions (13:05) Rashee Rice (15:56) Brian Thomas Jr. Trade Value (18:38) Outlook on Emeka Egbuka (20:52) John Harbaugh hiring (24:39) Chat Questions To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

Anthony and Alex dive into the reports that Todd Monken is the "leader in the clubhouse" to become the New York Giants' next offensive coordinator. After two elite seasons in Baltimore (including a #1 ranked offense in 2024), Monken is expected to reprise his role in East Rutherford and take Jaxson Dart to the next level. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nick Kostos explains what he expects from John Harbaugh and Jaxson Dart next season.

Jerry's got Jameis Winston talking about the football obsessed Jaxson Dart (all complimentary), the Knicks bad loss to Sacramento, the Mets pursuit of Kyle Tucker, and, of course, another loss by the Rangers.

Ken and Anthony discuss the importance of a quarterback in a coaching search and whether or not that may have swayed John Harbaugh's decision to go to the Giants.

Duel at High Noon – Can Harbaugh build a culture?, Is Harbaugh right for Dart?, Will the Jets draft a QB in the 1st 3 rounds? How great is the future for the Jets? Learn more about your ad choices. Visit podcastchoices.com/adchoices

Harbaugh to Giants; Dynasty Impact: Nabers, Dart, Skattebo

In this episode of DeHuff Uncensored, the NFL carousel goes completely off the rails. DeHuff breaks down the shocking move of John Harbaugh landing with the New York Giants on a massive five-year, $100 million deal, and why pairing him with Dart and Skattebo could finally mean big things for Big Blue. Meanwhile, Mike Tomlin steps down in Pittsburgh after 19 seasons, leaving the Steelers searching for just their fourth head coach since 1969. DeHuff explains this might be the end of an era in the Steel City. The episode also delivers a full Divisional Round playoff preview, including Rams at Bears, Texans at Patriots, 49ers at Seahawks, and Bills at Broncos. DeHuff digs into whether revenge is on the menu for Denver as they host Buffalo, with insight from Josh Allen, Bo Nix, and Sean Payton—who DeHuff suspects may be quietly stealing his ideas. To top it off, Von Miller weighs in with his prediction for the Bills–Broncos matchup, setting the stage for a weekend packed with drama, grudges, and postseason chaos. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Craig Carton and Chris McMonigle react to the Giants officially landing John Harbaugh, a move that instantly energizes Big Blue and saves a bleak New York sports winter. Craig celebrates the hire but pumps the brakes on over-the-top optimism, while Big Mac takes a victory lap and gives major credit to Joe Schoen for orchestrating the deal after months of criticism. The guys debate whether Giants fans almost got this wrong by wanting Shane fired, argue about John Mara's legacy as an owner, and take calls from fired-up listeners. Plus, a hilarious and revealing “game of honesty” breaks out as Big Mac is asked if he'd trade Jaxson Dart for just about every quarterback in the NFL with some shocking answers.

Mike Johnson, Ali Mac, and Beau Morgan react to the latest news, rumors, and reports in the NFL as they go In The Huddle.

On today's Carton Show, Big Mac and Craig Carton break down exclusive details from insider Connor Hughes about the Giants' head coaching search. Hear why Jaxson Dart's involvement in meeting John Harbaugh and other candidates is a smart move for the franchise's future. Plus, get the latest on Harbaugh's interview timeline, his upcoming visit with the Titans, and what it means for the Giants. They also dive into Aaron Rodgers' Jets tenure, the Mets' pitching rotation, and caller takes on Harbaugh's decision-making

While leading L&D at Creative Force, Aaron Horwath and his leaders began treating work as a product to be designed. That shift had wide effects, including something unexpected. Creative Force became one of the few companies to implement AI in a way that actually improved the experience of work. Instead of chasing tools, Aaron and his team started with people. In this episode, Dart and Aaron discuss why starting with people led to AI success, how work can be designed as a product, and what it takes to prepare humans for a fast-approaching future.Aaron Horwath is the Director of AI Operations at Creative Force. He helps teams redesign work by starting with people and using AI to reduce friction and improve the experience of work.In this episode, Dart and Aaron discuss:- Why AI should start with people, not tools- How treating work as a product changes everything- Finding the work that drains people and removing it- Using the bubble chart to redesign jobs- The difference between human work and AI work- How non technical teams are building real software- Why AI shortens the relay race of work- Why soft skills matter more in an AI world- How AI can make work more expressive- What leaders get wrong about AI adoption- And more…Aaron Horwath is the Director of AI Operations at Creative Force, where he leads the company's move toward AI augmented work. He previously led Learning and Development at the company, where he began treating work as a product and focusing on reducing friction in how people do their jobs. His work centers on starting with real business problems, understanding what work people love or hate, and using AI to remove low value tasks. Aaron takes a people first approach to AI, helping teams spend more time on meaningful, value generating work.Resources Mentioned:Creative Force: https://www.creativeforce.ioConnect with Aaron:LinkedIn: https://www.linkedin.com/in/aaronhorwathWork with Dart:Dart is the CEO and co-founder of the work design firm 11fold. Build work that makes employees feel alive, connected to their work, and focused on what's most important to the business. Book a call at 11fold.com.

Hr 2 - Cam Ward vs. Jaxson Dart: Who’s the better QB for John Harbaugh?See omnystudio.com/listener for privacy information.

Hr 2 - Cam Ward vs. Jaxson Dart: Who’s the better QB for John Harbaugh?See omnystudio.com/listener for privacy information.

Dr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT  Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at the City of Hope Cancer Center [in Los Angeles]. The field of rare cancer research is rapidly transforming thanks to progress in clinical trials and treatment strategies, as well as improvements in precision medicine and next-generation sequencing that enable biomarker identification. According to the National Cancer Institute, rare cancers occur in fewer than 150 cases per million each year, but collectively, they represent a significant portion of all cancer diagnoses. And we struggle with the appropriate treatment for these rare cancers in clinical practice. Today, I am delighted to be joined by Dr. Vivek Subbiah, a medical oncologist and the chief of early-phase drug development at the Sarah Cannon Research Institute in Nashville, Tennessee. Dr. Subbiah is the lead author of a paper in the ASCO Educational Book titled "Designing Clinical Trials for Patients with Rare Cancers: Connecting the Zebras," a great title for this topic. He will be telling us about innovative trial designs to enable robust studies for small patient populations, the promise of precision medicine, and novel therapeutic approaches to improve outcomes, and how we can leverage AI now to enroll more patients with rare cancers in clinical trials. Our full disclosures are available in the transcript of this episode.  Dr. Subbiah, it is great to have you on the podcast today. Thanks so much for being here. Dr. Vivek Subbiah: Thank you so much, Dr. Rugo, and it is an honor and pleasure being here. And thank you for doing this podcast for rare cancers. Dr. Hope Rugo: Absolutely. We are excited to talk to you. And congratulations on this fantastic paper. It is such a great resource for our community to better understand what is new in the field of rare cancer research. Of course, rare cancers are complex and multifaceted diseases. And this is a huge challenge for clinical oncologists. You know, our clinics, of course, cannot be designed as we are being very uni-cancer focused to just be for one cancer that is very rare. So, oncologists have to be a jack of all trades in this area. Your paper notes that there are approximately 200 distinct types of rare and ultra-rare cancers. And, by definition, all pediatric cancers are rare cancers. Of course, clinical trials are essential for developing new treatment strategies and improving patient outcomes, and in your paper, you highlight some unique challenges in conducting trials in this rare cancer space. Can you tell us about the challenges and how really innovative trial designs, I think a key issue, are being tailored to the specific needs of patients with rare cancer and, importantly, for these trials? Dr. Vivek Subbiah: Rare cancers present a perfect storm of challenges. First, the patient populations are very small, which makes it really hard to recruit enough participants for traditional type trials. Second, these patients are often geographically dispersed across multiple cities, across multiple states, across multiple countries, across multiple zip codes. So, logistics become complicated. Third, there is often limited awareness among clinicians, which delays referrals and diagnosis. Add to that regulatory hurdles, funding constraints, and you can see why rare cancer trials are so tough to execute. To overcome these barriers, we are seeing some really creative novel trial designs. And there are four different types of trial designs that are helping with enrolling patients with rare cancers. The first one is the basket trial. So let us talk about what basket studies are. Basket studies group patients based on shared genetic biomarkers or shared genetic mutations rather than tumor type. So instead of running separate 20 to 30 to 40 trials, you can study one therapy across multiple cancers. The second type of trial is the umbrella trial. The umbrella trials flip that concept of basket studies. They focus on one cancer type but test multiple targeted therapies within it. The third category of innovative trials are the platform studies. Platform trials are another exciting innovation. They allow new treatment arms to be added or removed as the data matures and as the data evolves, making trials more adaptive and efficient. The final category are decentralized tools in traditional trials, which are helping patients participate closer to where they are so that they can sleep in their own bed, which is, I think, a game changer for accessibility.  These designs maximize efficiency and feasibility for rare cancer research and rare cancer clinical trials. Dr. Hope Rugo: I love the idea of the platform trials that are decentralized. And I know that there is a trial being worked on with ARPA-H (Advanced Research Projects Agency for Health) funding in triple-negative breast cancer as well as in lung cancer, I think, and others with this idea of a platform trial. But it is challenged, I think, by precision medicine and next-generation sequencing where some patients do not have targetable markers, or there isn't a drug to target the marker. I think those are almost the same thing. We have really seen that these precision medicine ideas and NGS have moved the needle in helping to identify genetic alterations. This helps us to be more personalized. It actually helps with platform studies to customize trial enrollment. And we hope that this will result in better outcomes. It also allows us, I think, to study drugs even in the early stage setting more effectively. How can these advances be best applied to the future of rare cancers, as well as the challenges of not finding a marker or not having a drug? Dr. Vivek Subbiah: Thank you so much for that question. I think precision medicine and next-gen sequencing, or NGS, are truly the backbone of modern precision oncology. They have transformed how we think about cancer treatment. Instead of treating based on where the tumor originated or where the tumor started, we now look at the genetic blueprint of cancer. The NGS or next-gen sequencing allows us to sequence millions of DNA fragments quickly. Twenty, 30 years ago, they said we cannot sequence a human genome. Then it took almost a decade to sequence the first human genome. Right now, we have academic centers and commercial sequencing companies that are really democratizing NGS across all sites, not just in academic centers, across all the community sites, so that NGS is now accessible. This means that we can identify these actionable alterations like picking needles in haystacks, like NTRK fusions, RET fusions, or BRAF V600E alterations, high tumor mutational burden. This might occur across not one tumor type, across several different tumor types. So for rare cancers, this is critical because some of these mutations often define the best treatment option. Here is why this matters. Personalized therapy, right? Instead of a one-size-fits-all approach, we can tailor treatment to the patient's unique molecular profile. For trial enrollment, this can definitely help because patients can join biomarker-driven trials even if their cancer type is rare or ultra-rare. NGS technology has also helped us in designing rational studies. Many times monotherapy does not work in these cancers. So we are thinking about rational combination strategies. So NGS technology is helping us. Looking ahead, I see NGS becoming routine in clinical practice, not just at major niche academic centers, but everywhere. We will see more tumor-agnostic approvals, more molecular tumor boards guiding treatment decisions in real time. And I think we are seeing an expanded biomarker setup. Previously, we used to have only a few drugs and a handful of mutations. Now with homologous recombination defects, BRCA1/2 mutation, and expanding the HRD and also immunohistochemistry, we are expanding the biomarker portfolio. So again, I personally believe that the future is precision. What I mean by precision is delivering the right drug to the right patient at the right time. And for rare cancers, this isn't just progress. It is survival. And it is maybe the only way that they can have access to these cutting-edge precision medicines. Dr. Hope Rugo: That is so important. You mentioned an important area we will get to in a moment, the tumor-agnostic therapies. But as part of talking about that, do you think that the trials should also include just standard therapies? You know, who do you give an ADC to and when with these rare cancers? Because some of them do not have biomarkers to target and it is so disappointing for patients and providers where you are trying to screen a patient for a trial or a platform trial where you have one arm with this mutation, one arm with that, and they do not qualify because they only have a p53 loss, you know? They just do not have the marker that helps them. But we see this in breast cancer all the time. And it is tough because we don't have good information on the sequencing. So I wonder, you know, just because for some of these rare cancers it is not even clear what to use when with standard treatments. And then that kind of gets into this idea of the tumor-agnostic therapies that you mentioned. There are a lot of new treatments that are being evaluated. We have seen approval of some treatments in the last few years that are tumor-agnostic and based on a biomarker. Is that the best approach as we go forward for rare cancers? And what new treatment options are most exciting to you right now? Dr. Vivek Subbiah: Tumor-agnostic therapies, really close to my heart, are real breakthrough therapies and represent a major paradigm shift in oncology. Traditionally, for the broad listeners here, we are used to thinking about designing clinical trials and therapy like where the cancer originated, breast cancer, kidney cancer, prostate cancer, lung cancer. A tumor-agnostic therapy flips that model. Instead of focusing on the organ, they target the specific genetic alteration or biomarker that drives cancer growth regardless of where the tumor started, regardless of the location of the tumor, regardless of the zip code of the tumor. So why is this so important for rare cancers? Because many rare cancers share molecular features with more common cancers. For instance, NTRK fusion might occur in pediatric sarcoma, a salivary gland tumor, or a thyroid cancer. Historically, each of these would require separate trials, which is nearly impossible, unfeasible to conduct in these ultra-rare cancers like salivary gland cancer or pediatric sarcomas. Tumor-agnostic therapies allow us to treat all those cancers with the same targeted drug if they share that biomarker. Again, we are in 2025. The first tissue-agnostic approval, the historic precedent, was in fact an immunotherapy. Pembrolizumab was approved in 2017, May 2017, as the first immunotherapy to be approved in a tumor-agnostic way for a genomic biomarker, for MSI-High and dMMR cancers. Then came the NTRK inhibitors. So today we have not one, not two, but three different NTRK inhibitors: larotrectinib, entrectinib, and repotrectinib, which show response rates of nearly more than 60 to 75% across a handful of dozens and dozens of cancer types. Then, of course, we have RET inhibitors like selpercatinib, which is approved tissue-agnostic, and pralsetinib, which also shows tissue-agnostic activity across multiple cancers. And more recently, combination therapy with a BRAF and MEK combination, dabrafenib and trametinib, received tumor-agnostic approval for all BRAF V600E tumors with the exception of colorectal cancer. And even recently, you mentioned about antibody drug conjugates. Again, I think we live in an era of antibody drug conjugates. And Enhertu, trastuzumab deruxtecan, which was used first in breast cancer, now it is approved in a histology-agnostic manner for all HER2-positive tumors defined by immunohistochemistry 3+. So again, beyond NGS, now immunohistochemistry for HER2 is also becoming a biomarker. So again, for the broad listeners here, in addition to comprehensive NGS that may allow patients to find treatment options for these rare cancers for NTRK, RET, and BRAF, immunohistochemistry for HER2 positivity is also emerging as a biomarker given that we have a new FDA approval for this. So I would say personally that these therapies are game changers because they open doors for patients who previously had no options. Instead of waiting for years for a trial in their specific cancer type, they can access a treatment based on their molecular profile. I think it is precision medicine at its finest and best. Looking ahead, the third question you asked me is what is exciting going on? I think we will see more of these approvals. My hope is that today, I think we have nine to ten approvals. My hope is that within the next 25 to 50 years, we will have at least 50 to 100 drugs approved in this space based on a biomarker, not based on a location of the tumor type. Drug targeting rare alterations like FGFR2 fusions, FGFR amplifications, ALK fusions, and even complex signatures like high tumor mutational burden. I think we will be seeing hopefully more and more drugs approved. And as sequencing becomes routine, we will identify more patients for these therapies. I think for rare cancers, this is not just innovative approach. This is essential for them to access these novel precision medicines. Dr. Hope Rugo: Yeah, that is such a good point. I do think it is critical. Interestingly in breast cancer, it hasn't been, you know, there is always like two patients in these tumor-agnostic trials, or if that. You know, I think I have seen one NTRK fusion ever. I think that highlights the importance for rare cancers. And you know, I am hoping that that will translate into some new directions for some of our rarer and impossible-to-treat subtypes of breast cancer. It is this kind of research that is really going to make a difference. But what about those people who do not have biomarkers? What if you do not fit into that? Do you think there is a possibility of trying to do treatments for rare cancers in some prospective way that would help with that? You know, it is really a huge challenge. Dr. Vivek Subbiah: Absolutely. I think, you know, you're right, usually many of these rare cancers are driven by specific biomarkers. And again, some of the pediatric salivary gland tumors or pediatric sarcomas like fibrosarcomas, they are pathognomonic with NTRK fusions. And again, given that we have a tumor-agnostic approval, now these patients have access to these therapies. And I do not think that we would have had a trial just for pediatric fibrosarcomas with NTRK fusions. So that is one way. Another way is SWOG, right? The SWOG DART [1609] had this combination dual checkpoint, it was called the DART study dual combination chemotherapy with ipi/nivo. Now here the rare cancer subtype itself becomes a biomarker and they showed activity across multiple rare cancer subtypes. They didn't require a biomarker. As long as it was a rare or ultra-rare cancer, these patients were enrolled into the SWOG DART trial and multiple arms have read out. Angiosarcoma, Kaposi sarcoma, even gestational trophoblastic disease. Again, they have shown responses in these ultra-rare, rare cancers. Sometimes they might be seeing one or two cases a whole year. And I think this SWOG effort, this cooperative group effort, really highlighted the need for such studies without biomarkers as well. Dr. Hope Rugo: That is such a fantastic example of how to try and treat patients in a collaborative way. And in the paper, you also emphasize the need for collaborative research efforts, you know, uniting resource expertise across different ways of doing research. So cooperative groups, advocacy organizations that can really help advance rare cancer research, improve access to new therapies, and I think importantly influence policy changes. I think this already happened with the agnostic approvals. Could you tell us more about that? How can we move forward with this most effectively? Dr. Vivek Subbiah: Personally, I believe that collaboration is absolutely critical and essential for rare cancer research. No single institution, no single individual, or no single state or entity can tackle these challenges alone. The patient populations are small and dispersed. So pooling resources is the only way to run these meaningful trials. Again, it is not like singing, it is like putting a huge, huge, I would say, an opera piece together. It is not a solo, vocal therapy, but rather putting a huge opera piece like Turandot. You know, you mentioned cooperative groups. Cooperative groups, as I mentioned earlier, the SWOG DART program, the ASCO [TAPUR study]. ASCO is doing a phenomenal work of the TAPUR study. Again, this ASCO TAPUR program has enrolled so many patients with rare cancers who otherwise would not have treatment options. NCI-MATCH, the global effort, right? NCI-MATCH and the ComboMATCH are great examples. They bring together hundreds of sites, thousands of clinicians to run large-scale trials that would be impossible for any individual center or institution. These trials have already changed practice. For instance, the DART demonstrated the power of immunotherapy in rare cancers and influenced NCCN guidelines. One of the arms of the NCI-MATCH study from the BRAF V600E arm contributed towards the BRAF V600E tissue-agnostic approval. So, the BRAF V600E tissue-agnostic approval was by a pooled analysis of several studies. The ROAR study, the Rare Oncology Agnostic Research study, the NCI-MATCH dataset of tumor-agnostic cohort, and another pediatric trial, and also evidence from literature and evidence of case reports. And all this pooled analysis contributed to the tissue-agnostic approval of BRAF V600E across multiple rare cancers. There are several patient advocacy organizations which are the real unsung heroes here. Groups like, for instance, we mentioned in the paper, Target Cancer Foundation, don't just raise awareness for rare cancer research, they actively connect patients to trials providing financial, emotional support, and even run their own studies like the TRACK trial. They also influence policy to make access easier. On a global scale, initiatives like DRUP in the Netherlands, the ROME study in Italy, the PCM4EU in Europe are expanding precision medicine across these borders. These collaborations accelerate research, improve trial enrollment, and ensure patients everywhere can have access to these cutting-edge therapies. Again, it is truly a team effort, right? It is a multi-stakeholder approach. Researchers, clinicians, investigators, industry, regulators, academia, patients, patient advocates, and their caregivers all working together. And it takes a village. Dr. Hope Rugo: Absolutely. I mean, what a nice response to that. And I think really exciting and it is great to see your passion about this as well. But it helps all of us, I think, getting discouraged in treating these cancers to understand what is happening moving forward. And I think it is also a fabulous opportunity for our junior colleagues as they rise up in academics to be involved in these international collaborative efforts which are further expanding. One of the things that comes up for clinical trials for patients, and I think it is highlighted with rare cancers because, as you mentioned, people are all over the place, you know, they are so rare. They are all far away. Our patients are always saying to us, "Should I go here for a phase 1 trial?" Can you talk a little bit about how we can overcome these financial and geographic burdens for the patients? You talked about having trials locally, but it is a big financial and just social burden for patients. Dr. Vivek Subbiah: Great point. Financial cost is a major barrier in rare cancer clinical trials. It is a major barrier not just in rare cancer clinical trials, but in clinical trials in general. The economics of rare cancer research are one of the toughest challenges we face. Developing a new drug is already expensive, often billions of dollars. On an average, it takes 2 billion dollars or 2.8 billion dollars according to some data from drug discovery to approval. For rare cancers, the market is tiny, which means the pharmaceutical companies have really little financial incentive to invest. That is why initiatives like the Orphan Drug Act were created to provide tax credits, grants, and market exclusivity to encourage development for rare diseases. Clinical trials themselves are expensive because the small patient populations mean longer recruitment times and higher per-patient costs. Geographic dispersion, as you mentioned, for the patients adds travel, coordination. That is why we need to think out of the box about decentralized trial infrastructure so that we can mitigate some of these expenses. Complex trial designs like basket or platform trials sometimes require sophisticated data systems and regulatory oversight. That is a challenge. And I think some of the pragmatic studies like ASCO TAPUR have overcome those challenges. Advanced technologies like next-gen sequencing and molecular profiling also add significant upfront cost to this. Funding is also limited because rare cancers receive less attention compared to common cancers. Public funding and cooperative group trials help a lot, but I think they cannot cover everything. Patient advocacy organizations sometimes step in to bridge these gaps, but sustainable financing remains a huge challenge. So, the bottom line is without financial incentives and collaborating funding models, many promising therapies for rare cancers would never make it to patients. That is why we need system-wide policy changes, global partnerships, and innovative, effective, seamless trial designs which are so critical so that they can help reduce the cost and make research feasible so that we can deliver the right drug to the right patient at the right time. Dr. Hope Rugo: There is a lot of excitement about the future integration of AI in screening. Just at the San Antonio Breast Cancer meetings, we have a number of different presentations about AI to find markers, even like HER2, and using AI where you would screen and then match patients to clinical trials. Do you have any guidance for the rare cancer community on how to leverage this technology in order to optimize patient enrollment and, I think, identification of the best treatment matches? Dr. Vivek Subbiah: I think artificial intelligence, AI, is a game-changer in the making. Right now, clinical trial is clunky. Matching patients to trial is often manual, time consuming, laborious. You need a lot of personnel to do that. AI can automate this process by analyzing genomic data, medical records, and trial eligibility criteria to find the best matches quickly, accurately, and effectively. For the community, the key is to invest in data standardization and interoperability because AI needs clean, structured data to work effectively. Dr. Hope Rugo: Thank you so much, Dr. Subbiah, for sharing these fantastic insights with us on the podcast today and for your excellent article. Dr. Vivek Subbiah: Thank you so much. Dr. Hope Rugo: We thank you, our listeners, for joining us today. You will find a link to Dr. Subbiah's Educational Book article in the transcript of this episode. And please join us again next month on By the Book for more insightful views on key issues and innovations that are shaping modern oncology.  Thank you. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:        Dr. Hope Rugo   @hoperugo   Dr. Vivek Subbiah @VivekSubbiah Follow ASCO on social media:        ASCO on X  ASCO on Bluesky       ASCO on Facebook        ASCO on LinkedIn        Disclosures:       Dr. Hope Rugo:    Honoraria: Mylan/Viatris, Chugai Pharma   Consulting/Advisory Role: Napo Pharmaceuticals, Sanofi, Bristol Myer   Research Funding (Inst.): OBI Pharma, Pfizer, Novartis, Lilly, Merck, Daiichi Sankyo, AstraZeneca, Gilead Sciences, Hoffman La-Roche AG/Genentech, In., Stemline Therapeutics, Ambryx   Dr. Vivek Subbiah: Consulting/Advisory Role: Loxo/Lilly, Illumina, AADI, Foundation Medicine, Relay Therapeutics, Pfizer, Roche, Bayer, Incyte, Novartis, Pheon Therapeutics, Abbvie Research Funding (Inst.): Novartis, GlaxoSmithKline, NanoCarrier, Northwest Biotherapeutics, Genentech/Roche, Berg Pharma, Bayer, Incyte, Fujifilm, PharmaMar, D3 Oncology Solutions, Pfizer, Amgen, Abbvie, Mutlivir, Blueprint Medicines, Loxo, Vegenics, Takeda, Alfasigma, Agensys, Idera, Boston Biomedical, Inhibrx, Exelixis, Amgen, Turningpoint Therapeutics, Relay Therapeutics Other Relationship: Medscape, Clinical Care Options

https://m.ebay.co.uk/sch/i.html?sid=tindogpodcast&_pgn=1&isRefine=true&_trksid=p4429486.m3561.l49496 Stranger Things Season 2 (Fall 1984) deepens the mystery of the Upside Down, focusing on Will Byers being haunted and possessed by a massive shadow entity, the Mind Flayer, which uses him as a spy to spread its influence in Hawkins through underground tunnels, while Eleven discovers her past and reunites with friends, and the gang faces new threats like Demodogs, leading to a fight to close the gate and save Will and the town. New characters, including the pragmatic Max Mayfield, join the crew, and storylines explore the aftermath of Season 1, including Barb's legacy and Hopper's secret with Eleven. Key Plot Points: Will's Possession: Will suffers from terrifying visions of the Mind Flayer after a tentacle attaches to him, becoming a puppet for the monster's hive mind. The Mind Flayer's Plan: The shadow monster tries to expand the Upside Down into their world, creating tunnels beneath Hawkins. Eleven's Journey: El lives hidden with Hopper but eventually leaves to find her mother and learns about her origins, returning to help her friends. New Threats: The group encounters Demodogs (Demogorgon pups), and Dustin adopts a creature he names Dart, a pollywog from the Upside Down. New Faces: Max Mayfield (Max) arrives as a new student, challenging the group dynamic, while Joyce dates Bob Newby. Justice for Barb: Nancy and Jonathan team up with conspiracy theorist Murray Bauman to expose the truth about Barb's death.

Today on The Pivot Podcast, we're joined by one of the NFL's most dominant edge rushers — Brian Burns. Coming off a record-breaking season with the New York Giants, where he racked up 16.5 sacks — second most in the NFL behind Myles Garrett, Brian opens up about the defining moments of his career and the evolution of his game. He reflects on leaving the Carolina Panthers, what that transition meant personally and professionally, and how embracing change pushed him to another level. Brian opens up on his personal experience on the NFL being a business and no matter how many times you hear it, you don't truly know until you've gone through it and the impact of leaving a city he thought would be his career-home. Despite a record-setting year for Burns, the team success of Giants is something that weighs on him and is committed to turning his focus to building off the positives and has high hopes for what a new coach will add to the organization. From key veteran leadership to the electric play of quarterback Jaxon Dart, Brian believes New York's future is bright because of Dart's confidence, the skill level of offensive weapons, and young bulls like Adbul Carter being a fierce competitor with strong years ahead. Brian also gets candid about family, the role they've played in keeping him grounded, and how perspective off the field fuels excellence on it. From navigating expectations in a new city to discussing the future of the Giants, leadership, and legacy, this conversation goes far beyond stats and highlights. And of course, the guys have some laughs, as Channing knows Brian from the time he was a young boy living in south Florida as they exchange some stories of how Brian remembers Channing from back then haha. And that spirited love continues to now as Channing gets on him about having grown man hobbies vs the anime collection he boasts. This is an honest, insightful look into the mindset of an elite competitor — one who understands that growth, sacrifice, and purpose are just as important as production. Pivot Family, please like, comment and hit the subscribe button, we love hearing from you and appreciate the support always! Learn more about your ad choices. Visit megaphone.fm/adchoices

The guys kick off Wild Card Weekend by laying out their “selfish rooting interest” list, where Jets bitterness, Giants coaching paranoia, and pure chaos all collide. It starts with Rams-Panthers and a very specific agenda: hope Carolina's Bryce Young doubt grows just enough to create more QB options for the Jets, while also keeping the Panthers from becoming a real future threat. Then it turns into Bears-Packers, where personal grudges (Ben Johnson), weather talk, and the dream of a coaching-search circus take center stage. If the Packers lose, does it crack open another job and send the league into full-blown coach chaos? That's the debate. They hit Bills-Jaguars with the “maximum pain” theory for Buffalo fans, plus the Harbaugh ripple effects in Eagles-Niners, before the segment swerves into the Saquon billboard drama that feels like a direct shot at Giants fans. The back half includes Knicks-Wizards draft-pick paranoia, Giants OC continuity talk (Kafka and the Dart development angle), and a mini debate on why you can't blindly trust AI without fact-checking.

It's Wild Card Weekend, so we're playing the most dangerous game: who are we selfishly rooting for and why. The guys go matchup by matchup with Jets and Giants agendas all over the place, from hoping Carolina creates Bryce Young doubt (hello, Jets QB options) to rooting for pure chaos in Bears-Packers if it means more coaching openings. They also hit Bills-Jaguars, Eagles-Niners (and the John Harbaugh fear factor), plus the Patriots as the ultimate “please lose” postseason villain. Then it turns into full New York sports radio perfection: Cinco de Luncho takes over, Evan's brain gets exposed, and the crew reacts to the Saquon Barkley billboard shot at Giants fans on I-95. Hour 3 also dips into Knicks/Wizards draft-pick drama, Giants coordinator continuity talk (Kafka, Dart development), and a college QB watch that turns tonight's game into a Jets scouting mission. Key moments: rooting-interest power rankings, Giants coaching search circus, Saquon billboard outrage, Cinco de Luncho, and the phones lighting up with callers.

Rookie quarterback Jaxson Dart sits down with Madelyn Burke to discuss his rookie season in Giants Conversation presented by Jo Malone.See omnystudio.com/listener for privacy information.

Join us for a deep dive into the "SELF DRIVE Act" of 2026, a bipartisan bill aiming to dismantle state-level regulatory patchworks for autonomous trucking. This legislation promises legal certainty for cab-less truck designs and establishes a national safety data repository to replace fragmented reporting mandates. We also analyze the Federal Motor Carrier Safety Administration's plan to restore the 30-day automatic emergency relief window for hours-of-service rules. This reversal addresses the uncertainty and delays caused by the previous 14-day limit during recent disasters like the Key Bridge collapse and regional hurricanes. The conversation shifts to a critical compliance failure in North Carolina, where a DOT audit revealed that over half of commercial licenses issued to foreign drivers were illegal. The state now faces a potential $50 million funding loss and decertification of its CDL program if immediate corrective actions aren't taken. On the business front, we cover the acquisition of Dart Transit by Avkha Equity Holdings, marking the end of nine decades of family ownership for the Minnesota-based carrier. Additionally, we look at the revolving door at the Federal Maritime Commission as longtime Chief of Staff Mary Thien Hoang departs for a partner role at a D.C. lobbying firm. Finally, we explore why analysts have upgraded American Airlines and Sun Country, citing a robust recovery in air travel and resilient cargo operations. Sun Country's hybrid model and partnership with Amazon are highlighted as key drivers for substantial free cash flow projections. Follow the FreightWaves NOW Podcast Other FreightWaves Shows Learn more about your ad choices. Visit megaphone.fm/adchoices

In Friday's edition of Quick Hits, Nick and Jonathan react to Jaxson Dart's lip reading on the sideline, as well as if the SEC's dominance will ever come back.

Hour 4: Jaxson Dart Spills Beans On Next Head Coach, Carton Show 1st Week Wrap-Up

Shannon Sharpe and Chad “Ochocinco” Johnson provide the most captivating NFL moments from 2025. They react to the sheer madness surrounding Shedeur Sanders’ rookie season with the Cleveland Browns. Unc and Ocho are left speechless by the Dallas Cowboys’ shocking trade of Micah Parsons to the Green Bay Packers and Ja’Marr Chase spitting on Jalen Ramsey! Subscribe to Nightcap presented by PrizePicks so you don’t miss out on any new drops! Download the PrizePicks app today and use code SHANNON to get $50 in lineups after you play your first $5 lineup! Visit https://prizepicks.onelink.me/LME0/NI... 0:00 - Micah traded to Packers24:00 - Ja’Marr Chase suspended for spitting36:52 - Bears stun Packers in OT with Caleb Williams to DJ Moore walk-off TD45:30 - Jets bench Justin Fields55:28 - Bills Sit Keon Coleman Again1:05:13 - Dart and Skat SHOCK Eagles (Timestamps may vary based on advertisements.) #ClubSee omnystudio.com/listener for privacy information.

Hour 3 centers on the question Giants fans actually want answered: why Joe Schoen is still the general manager. Evan and Shaun react to Schoen's press conference and replay his explanation for keeping the job, then rip apart the idea that the Giants have merely “stubbed their toe.” The discussion turns into a blunt breakdown of accountability, ownership patience, and whether Schoen is underselling just how bad things have gone. The hour also dives into whether Jaxson Dart should have any input in the next head coaching hire. Schoen's dismissive answer sparks frustration, with Evan arguing that listening to your young quarterback does not mean handing him the keys. The guys explain why ignoring Dart's perspective sends the wrong message about development, leadership, and the future of the franchise. From there, the Giants coaching search opens back up. Kevin Stefanski, Mike McCarthy, Rex Ryan, Bill Belichick, and surprise candidates all come up, with a focus on who the Giants are most likely to hire rather than who fans want. Callers weigh in on dynastic ownership, why bad owners only fix things by accidentally hiring the right person, and whether the Giants should slow the process in case a major name becomes available. The hour ends with classic show chaos, including Jets misery comparisons, Olympic hockey arguments, media access stories, and a reminder of the hard truth of fandom: you scream, you argue, and then you hope you are wrong.

Evan and Shaun dive into two key moments from Joe Schoen's press conference and why Giants fans still aren't buying what he's selling. First, they react to Schoen being asked to justify keeping his job, and why his “course correction” explanation feels like it minimizes how bad things have gotten. Shaun lays out the kind of brutally honest answer he wishes Schoen gave, one that actually owns the misses and explains why the last two years should matter. Then comes the big topic that Giants fans care about most: should Jaxson Dart have any input on the next head coach? Schoen dismissing it sparks a debate about leadership, ego, and whether ignoring your young quarterback's perspective is a massive mistake even if he's not making the decision. The segment rolls into more Giants coaching talk with calls on what the team needs most, why waiting could matter in case a surprise candidate shakes loose, and the idea that the only thing that truly fixes “dynastic ownership” is accidentally hiring the right person and staying out of the way. Plus, a quick detour into Big Mac's Dolan interview bet story, and whether the Giants should at least have a conversation with Bill Belichick before making the biggest hire of the offseason.

Nick and Jonathan react to the best sound bites and storylines from around the sports and entertainment world.

Every building comes with a set of expectations. Students are quiet in a library, but loud on a playground. Adults are focused in their deckchairs yet chatty on bar stools. Witnessing the limitations of conventional building design, Jan Golembiewski began to leverage design psychology to improve the lives of different groups, from inmates to the elderly. As one of the world's leading researchers in architectural design psychology, Dr. Golembiewski works to create spaces that prioritize health and overall flourishing.In this revisited episode, Dart and Jan discuss how salutogenic design works, how the spaces around us shape the way we think and feel, and what it means to create workplaces and buildings where people can truly thrive.Dr. Jan Golembiewski is an architect and researcher focused on the psychology of the built environment. He studies how design can support health, dignity, and human flourishing.In this episode, Dart and Jan discuss:- A unique design approach called salutogenesis- Designing a workplace where employees can thrive- Salutogenic architecture- Balancing affordances and choices in design- The narrative context embedded in architecture- How money-driven architecture affects livability- The key traits of salutogenic architects- And other topics…Dr. Jan Golembiewski is an architect and researcher who specializes in the psychology of the built environment. He is the director and nominated architect of Psychological Design and the co-founder and CEO of Earthbuilt Technology. His work explores how architectural settings affect health, behavior, and well-being, with a particular focus on salutogenic design. Golembiewski received his Ph.D. in architecture from the University of Sydney and has served as an adjunct professor and a judge for international design and health awards.Resources mentioned:Claus Raasted and Paul Bulencea on Work for Humans: https://podcasts.apple.com/us/podcast/the-art-of-transformation-experience-design/id1612743401?i=1000623034271 The Battle for the Life and Beauty of the Earth, by Christopher Alexander: https://www.amazon.com/Battle-Life-Beauty-Earth-World-Systems/dp/0199898073Magic, by Jan Golembiewski: https://www.amazon.com/Magic-Jan-Golembiewski-ebook/dp/B07J5RNFWVConnect with Jan:Website: www.psychological.designLinkedIn: https://www.linkedin.com/in/jan-golembiewski-a4802a15/ Google Scholar: https://scholar.google.com/citations?user=vwuUGOkAAAAJ&hl=en&oi=aoWork with Dart:Dart is the CEO and co-founder of the work design firm 11fold. Build work that makes employees feel alive, connected to their work, and focused on what's most important to the business. Book a call at 11fold.com.

Glen West, a senior writer at Geaux247 Sports, joined Sports Talk. West broke down LSU's pursuit of Arizona State quarterback Sam Leavitt. West also shared his thoughts on new LSU safety Ty Benefield, defensive lineman Stephiylan Green, and the Tigers' offensive line needs.

Glen West, a senior writer at Geaux247 Sports, joined Sports Talk. West broke down LSU's pursuit of Arizona State quarterback Sam Leavitt. West also shared his thoughts on new LSU safety Ty Benefield, defensive lineman Stephiylan Green, and the Tigers' offensive line needs.

Did the Giants prove anything with these last 2 wins? Steve Young says Dart has shown signs of being a good quarterback but you have to go do it and it takes a lot of help to get there. Learn more about your ad choices. Visit podcastchoices.com/adchoices

(1:00) – Connor shocks Matthew and Jay by admitting to knowing very little about Star Wars(8:15) – Rotoworld Player News: Tyler Loop misses game-winning kick, projecting Kenneth Gainwell and Derrick Henry in 2026, buying/selling Michael Wilson next season, Matthew Stafford's MVP case, ranking Colston Loveland among TEs(33:00) – More Week 18 Reaction: Expectations for Jaxson Dart and Jaydon Blue in sophomore seasons, Rhamondre Stevenson vs TreVeyon Henderson ADP next year(40:40) – Black Monday Headlines: Raiders let go of Pete Carroll, Browns fire Kevin Stefanski, Falcons cut ties with Raheem Morris(44:05) – Weekend Warriors: Trevor Lawrence, Parker Washington, Mitch Trubisky, Ray Davis, Tyler Shough, Chase Brown, Justin Jefferson, Tank Bigsby, Alec Pierce(49:30) – Last Call: Betting the exact Super Bowl result, the Jaguars to win the AFC, and Eagles to win the NFC Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Giants land the fifth pick as we debate potential coaching moves and Kevin Stefanski's future. Jerry kicks off his update with the sounds of Big Blue's win over Dallas, Jaxson Dart's message to the fans, and the Jets' historic interception-less season. We also dive into the "Holy Water" missed field goal that sent the Steelers to the playoffs and the controversy surrounding Myles Garrett's sack record. Finally, we break down Dart's Mahomes-like flip play and a questionable coaching decision by the Ravens.

Wide receiver Darius Slayton speaks to the media Sunday after the Giants' Week 18 win over the Cowboys.See omnystudio.com/listener for privacy information.

Guard Greg Van Roten speaks to the media Sunday after the Giants' Week 18 win over the Cowboys.See omnystudio.com/listener for privacy information.

Quarterback Russell Wilson speaks to the media Monday following the conclusion of the 2025 season.See omnystudio.com/listener for privacy information.

After calling the game for the New York Giants' win over the Dallas Cowboys, Bob Papa and Carl Banks highlight Jaxson Dart's performance and why he could be a franchise-changing player. Carl stresses the importance of Dart, along with other young building blocks like Abdul Carter and Cam Skattebo, in reshaping the team's culture. He encourages fans to listen to Dart's postgame press conference, where Dart focuses on improving the team and finally snapping the losing streak against Dallas. Carl also praises Tyrone Tracy's performance and notes the boost that comes from having a quarterback who truly believes this team can win. They also share coaches who may be retained. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tight end Daniel Bellinger speaks to the media Sunday after the Giants' Week 18 win over the Cowboys.See omnystudio.com/listener for privacy information.

(3:15) – Rotoworld Player News: Lamar Jackson solidifies playing status at Steelers(10:35) – QB Love/Hate: Jaxson Dart, Trevor Lawrence, Caleb Williams(17:00) – RB Love/Hate: Chase Brown, RJ Harvey, Omarion Hampton(22:10) – WR + TE Love/Hate: George Pickens, Colston Loveland, Michael Pittman Jr.(33:15) – Week 18 Player Incentives: Ashton Jeanty, Tony Pollard, Justin Jefferson, CeeDee Lamb, Trey McBride(46:20) – Week 18 Regular Power Rankings(47:35) – What's on Tap: Trusting Drake London vs Saints, Chase Brown vs Quinshon Judkins vs Nico Collins vs Garrett Wilson in a keeper league + Who could rise most in the 2026 rankings this offseason?(51:20) – Last Call: Jay and Connor pitch Matthew on a Derrick Henry prop and a side in Jets-Bills Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This hour, Boomer defends Aaron Glenn's future with the Jets and asks if the Giants can pull a "worst-to-first" turnaround with the right coach. We breakdown draft targets for both teams before Jerry delivers a bizarre update featuring GWAR action figures and the misery of the Jets' season finale in the Buffalo snow. Plus, Jaxson Dart's future with Malik Nabers, the Jets' historic lack of interceptions, and a legendary "Moment of the Day" from Dart's dad. We wrap it all up with our Week 18 NFL Picks!

Art gets us ready for Sunday's match-up against the Dallas Cowboys at MetLife Stadium. Coaching candidates, Jaxson Dart, and more as we get ready for the offseason.

Shaun Morash and Tiki Barber lament the discourse surrounding Giants quarterback Jaxson Dart, whether or not Tyler Shough has a better case for OROY than him, and get fired up over the narrative that he is prone to concussions because of his playstyle.

Shaun Morash and Tiki Barber discuss a pregame non-report from Ian Rapoport that Joe Schoen is expected to stay as the Giants' general manager "through the draft," as well as Jaxson Dart's standing with the organization.

Shaun Morash and Tiki Barber spend the second hour of Monday's show discussing the Giants futures of General Manager Joe Schoen and first-round draft pick Jaxson Dart, as well as filtering in some news around the NFL.

Jerry and CMac trace the Giants' rise and fall—from the Jaxson Dart "playoff" hype to the Denver interception that changed everything. We're breaking down the Jets' "unwatchable" defense, Aaron Glenn's failing culture, and CMac's question about why NFL players never actually use their mouthguards. Plus, Jaxon Dart looking better out there, a mysterious "alien" noise in the studio, and a heartfelt tribute to 104-year-old WWII veteran Dominick Critelli's legendary saxophone anthem.

Jerry and CMac aren't holding back after a weekend that saw the Jets reach a new low and the Giants win a game their fans wanted them to lose. From Jerry's "grounds for firing" verdict on the Jets' lack of effort to a wild pitch to hire Brian Daboll as a savior for the next New York QB, we're dissecting the disaster. Plus: Jaxson Dart's strong game and a 49ers/Bears shootout.